AVIR AVIR

Atea Pharmaceuticals Stock Price

8.69
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
8.69
Volume 0
Bid Price 8.23
Ask Price 8.70
News -
Day High

Low
7.37

52 Week Range

High
94.1737

Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Atea Pharmaceuticals Inc AVIR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 8.69 19:00:00
Open Price Low Price High Price Close Price Prev Close
8.69
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 8.69 USD

Period:

Draw Mode:

Atea Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 722.16M 83.10M 61.39M $ 48.63M $ 5.78M -0.63 -85.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 1.90%

more financials information »

Atea Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AVIR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.6858.7257.648.191,636,7641.0113.08%
1 Month10.695211.727.378.602,926,261-2.01-18.75%
3 Months25.6846.90997.3717.995,324,942-16.99-66.16%
6 Months23.8546.90997.3719.813,197,060-15.16-63.56%
1 Year28.4794.17377.3722.601,890,416-19.78-69.48%
3 Years29.9494.17377.3722.821,761,427-21.25-70.98%
5 Years1.2894.17370.43118.801,047,9417.41578.91%

Atea Pharmaceuticals Description

Atea Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.


Your Recent History
NASDAQ
AVIR
Atea Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.